Patents by Inventor Robert L. Lewis

Robert L. Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190134321
    Abstract: A device for delivering medication to a user may include a main body, an electronics module, and a slider. The main body may include a mouthpiece, a medication reservoir, and a mouthpiece cover, where the mouthpiece cover may be hinged to the main body. The electronics module may include a communication circuit, a pressure sensor, and a switch. The slider may be configured to engage the switch when the mouthpiece cover moves from a closed position to an open position. The switch may be configured to switch the electronics module from an off state or a sleep state to an active state. The electronics module may be configured to never return to the off state after the mouthpiece cover is moved to expose the mouthpiece for the first time by the user.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 9, 2019
    Applicant: Norton (Waterford) Limited
    Inventors: Enrique Calderon Oliveras, Carl L. Lewis, Symon D'Oyly Cotton, Steven D. Gardner, Robert O. Kivlin
  • Patent number: 10150784
    Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: December 11, 2018
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventor: Robert L. Lewis
  • Publication number: 20180303777
    Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.
    Type: Application
    Filed: April 9, 2018
    Publication date: October 25, 2018
    Inventor: Robert L. Lewis
  • Publication number: 20180161365
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: Robert L. Lewis, Charles E. Day
  • Patent number: 9889157
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: February 13, 2018
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventors: Robert L. Lewis, Charles E. Day
  • Publication number: 20170335794
    Abstract: An ice storage unit including a housing defining an interior portion and a heat exchange engine disposed within the interior portion, the heat exchange engine defining a thermal exchange element extending therefrom. A thermally conductive coupling element defining an aperture is sized to receive the thermal exchange element therein. A thermally conductive reservoir is disposed proximate the thermally conductive coupling element.
    Type: Application
    Filed: May 18, 2017
    Publication date: November 23, 2017
    Inventors: Jason S. SHERMAN, D. Paul HAVILAND, Robert L. LEWIS, JR., Grayson P. NEWLAND, Sumner E. P. ADAMS
  • Publication number: 20170202875
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Application
    Filed: April 3, 2017
    Publication date: July 20, 2017
    Inventors: Robert L. Lewis, Charles E. Day
  • Patent number: 9610267
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 4, 2017
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventors: Robert L. Lewis, Charles E. Day
  • Publication number: 20160326188
    Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.
    Type: Application
    Filed: July 18, 2016
    Publication date: November 10, 2016
    Inventor: Robert L. Lewis
  • Publication number: 20160256420
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Application
    Filed: May 16, 2016
    Publication date: September 8, 2016
    Inventors: Robert L. Lewis, Charles E. Day
  • Patent number: 9394318
    Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: July 19, 2016
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventor: Robert L. Lewis
  • Patent number: 9339481
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: May 17, 2016
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventors: Robert L. Lewis, Charles E. Day
  • Publication number: 20140186408
    Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.
    Type: Application
    Filed: November 26, 2013
    Publication date: July 3, 2014
    Applicant: Cypress Pharmaceutical, Inc.
    Inventor: Robert L. Lewis
  • Publication number: 20120282352
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Application
    Filed: July 9, 2012
    Publication date: November 8, 2012
    Applicant: CYPRESS PHARMACEUTICAL, INC.
    Inventors: Robert L. Lewis, Charles E. Day
  • Publication number: 20120277183
    Abstract: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.
    Type: Application
    Filed: July 9, 2012
    Publication date: November 1, 2012
    Applicant: CYPRESS PHARMACEUTICAL, INC.
    Inventors: Robert L. Lewis, Charles E. Day
  • Patent number: 8247000
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: August 21, 2012
    Assignee: Cypress Pharmaceutical, Inc.
    Inventors: Robert L. Lewis, Charles E. Day
  • Patent number: 8236358
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and an enteric coating.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: August 7, 2012
    Assignee: Cypress Pharmaceutical, Inc.
    Inventors: Robert L. Lewis, Charles E. Day
  • Publication number: 20120195964
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and an enteric coating.
    Type: Application
    Filed: April 12, 2012
    Publication date: August 2, 2012
    Applicant: CYPRESS PHARMACEUTICAL, INC.
    Inventors: Robert L. Lewis, Charles E. Day
  • Patent number: 7943597
    Abstract: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: May 17, 2011
    Assignee: Cypress Pharmaceutical, Inc.
    Inventors: Robert L. Lewis, Charles E. Day
  • Patent number: D830430
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: October 9, 2018
    Assignee: Beyond Zero, Inc.
    Inventors: Jason S. Sherman, D. Paul Haviland, Sumner E. P. Adams, Grayson P. Newland, Robert L. Lewis, Jr.